← Back to Search

MM120 for Anxiety

Phase 3
Recruiting
Research Sponsored by Mind Medicine, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are you willing to abstain from cannabis use for at least 12 weeks while you participate in the study?
Are you willing to use contraception throughout the study period?
Must not have
Have you used psychedelics in the past 2 years? e.g. LSD, MDMA, DMT, psilocybin, ayahuasca, mescaline, mushrooms, ecstasy
Have you or an immediate family member (child, sibling, parent) ever been diagnosed with Schizophrenia or Bipolar Disorder?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks

Summary

The reason for this study is to see if the investigational study drug, called MM120, can help people with Anxiety compared to a placebo. A placebo is an inactive drug that looks like MM120 but does not contain any active ingredients.

Eligible Conditions
  • Anxiety

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This study's timeline: screening for a total of 30 days, Double Blind Period for a total of 12 weeks, and an Open Label Extension for a total of 56 weeks.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the efficacy of a single dose of MM120 versus placebo on anxiety symptoms in adults with GAD
Secondary study objectives
To evaluate the efficacy of a single dose of MM120 versus placebo on additional measures of anxiety, functioning and quality of life in adults with GAD

Study Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MM120Experimental Treatment1 Intervention
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Group II: PlaceboPlacebo Group1 Intervention
An inactive drug that looks like MM120 but does not contain any active ingredients.

Find a Location

Who is running the clinical trial?

Mind Medicine, Inc.Lead Sponsor
~64 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top